WE CLAIM:

1. A storage stable fosinopril tablet comprising fosinopril and a combination of colloidal silicon dioxide and talc.

2. The storage stable tablet of claim 1, wherein the fosinopril comprises one or more of free fosinopril acid and pharmaceutically acceptable salts of fosinopril.

3. The storage stable tablet of claim 2, wherein the pharmaceutically acceptable salt of fosinopril comprises one or more of fosinopril sodium, fosinopril magnesium and fosinopril calcium.

4. The storage stable tablet of claim 3, wherein the pharmaceutically acceptable salt comprises fosinopril sodium.

5. The storage stable tablet of claim 1, wherein the colloidal silicon dioxide comprises from about 0.25% to about 10% by weight of the total tablet weight.

6. The storage stable tablet of claim 1, wherein the talc comprises from about 0.25% to about 5% by weight of the total tablet weight.

7. The storage stable tablet of claim 1, wherein the tablet further comprises one or more pharmaceutically acceptable excipients.

8. The storage stable tablet of claim 7, wherein the one or more pharmaceutically acceptable excipients comprise one or more of diluent, disintegrant, binder, coloring agent, and flavoring agent.

9. The storage stable tablet of claim 8, wherein the diluent comprises one or more of calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, cellulose-microcrystalline, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sorbitol, starch, starch pregelatinized, sucrose, sugar compressible and sugar confectioners.

10. The storage stable tablet of claim 9, wherein the diluent comprises lactose.

11. The storage stable tablet of claim 8, wherein the binder comprises one or more of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,

polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, alginic acid derivatives and propylene glycol, and alginate.

12. The storage stable tablet of claim 11, wherein the binder comprises polyvinylpyrrolidone.

13. The storage stable tablet of claim 8, wherein the disintegrant comprises one or more of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, croscarmellose sodium, starch, crystalline cellulose, hydroxypropyl starch, and partly pregelatinized starch.

14. The storage stable tablet of claim 13, wherein the disintegrant comprises croscarmellose sodium.

15. The storage stable tablet of claim 1, wherein the tablet further comprises one or more additional active ingredients.

16. The storage stable tablet of claim 15, wherein the one or more additional active ingredients comprise a diuretic comprising one or more of chlorthalidone, furosemide, triameterene, amiloride, spironolactone, and thiazide diuretics.

17. The storage stable tablet of claim 16, wherein the thiazide diuretic comprises one or more of chlorothiazide, hydrochlorothiazide, flumethiazide and bendroflumethiazide.

18. The storage stable tablet of claim 17 wherein the thiazide diuretic comprises hydrochlorothiazide.

19. The storage stable tablet of claim 15, wherein the one or more additional active ingredients comprise one or more of antidepressants, antidiabetics, antiulcers, analgesics, antihypertensives, antibiotics, antipsychotics, antineoplastics, antimuscarinics, diuretics, antimigraine agents, antivirals, anti-inflammatory agents, sedatives, antihistaminics, antiparasitic agents, antiepileptics and lipid lowering agents.

20. The storage stable tablet of claim 15, wherein the one or more additional active ingredients comprise one or more of enalapril, captopril, benazepril, lisinopril, ranitidine, famotidine, ranitidine bismuth citrate, diltiazem, propranolol, verapamil, nifedipine, acyclovir, ciprofloxacin, simvastatin, atorvastatin, lovastatin, divalproex, venlafaxine, citalopram, paroxetine, selegiline, midazolam, fluoxetine, acarbose, buspirone, nimesulide, captopril, nabumetone, glimepiride, glipizide, etodolac, nefazodone and their pharmaceutically acceptable salts.

21. The storage stable tablet of claim 1, wherein greater than approximately 98% of an initial amount of fosinopril sodium remains after storage for three months at 40°C and 75% relative humidity as measured by high performance liquid chromatography.

22. The storage stable tablet of claim 1, wherein greater than approximately 98% of an initial amount of fosinopril sodium remains after storage for one week at 60°C as measured by high performance liquid chromatography.

23. The storage stable tablet of claim 22, wherein greater than approximately 99% of an initial amount of fosinopril sodium remains after storage for one week at 60°C as measured by high performance liquid chromatography.

24. The storage stable tablet of claim 1, wherein greater than approximately 98% of an initial amount of fosinopril sodium remains after storage for one week at 60°C as measured by high performance liquid chromatography.

25. The storage stable table of claim 7, wherein the tablet comprises approximately 20% by weight of fosinopril sodium, approximately 45% by weight of anhydrous lactose, approximately 20% by weight of microcrystalline cellulose, approximately 3.5% by weight of crospovidone, approximately 5% by weight of polyvinylpyrrolidone, approximately 2.5% by weight of colloidal silicon dioxide, and approximately 4.0% by weight of talc.

26. A storage stable fosinopril tablet comprising:
from about 1% to about 40% by weight fosinopril sodium;
up to 25% by weight of a diuretic;

from about 20% to about 85% by weight of diluent;
from about 1% to about 10% by weight of disintegrant;
from about 1% to about 10% by weight of binder;
from about 0.25% to about 10% by weight of colloidal silicon dioxide; and
from about 0.25% to about 5% by weight of talc,
wherein the weights are percentages of the total tablet weight.

27. A process for preparing storage stable fosinopril tablets, the process comprising the steps of:
a. blending fosinopril in one or more of its free acid form and its pharmaceutically acceptable salts with one or more pharmaceutically acceptable excipients to form a blend,
b. optionally granulating the blend to form granules;
c. lubricating the blend or granules with colloidal silicon dioxide and talc; and
d. compressing into tablets.

28. The process according to claim 27, further comprising granulating the blend of step (a).

29. The process according to claim 28, wherein granulating the blend of step (a) comprises a wet granulation process.

30. The process according to claim 28, wherein granulating the blend of step (a) comprises a dry granulation process.

31. The process according to claim 27, wherein the blend of step (a) further comprises one or more additional active ingredients.

32. The process according to claim 31, wherein the additional active ingredient comprises one or more of a diuretic comprising chlorthalidone, furosemide, triameterene, amiloride, spironolactone, and thiazide diuretics.

33. The process according to claim 32, wherein the thiazide diuretic comprises one or more of chlorothiazide, hydrochlorothiazide, flumethiazide and bendroflumethiazide.

34. The process according to claim 33, wherein the thiazide diuretic comprises

hydrochlorothiazide.

35. The process according to claim 27, further comprising using high performance liquid chromatography to measure the amount of fosinopril after storage.

36. The process according to claim 35, wherein greater than approximately 98% of an initial amount of fosinopril remains after storage for three months at 40°C and 75%, the amount of fosinopril being measured by high performance liquid chromatography.

37. The process according to claim 35, wherein greater than approximately 99% of an initial amount of fosinopril remains after storage for one week at 60°C, the amount of fosinopril being measured by high performance liquid chromatography.

38. A method for one or more of treating hypertension in a mammal and the management of heart failure as an adjunctive therapy in a mammal, the method comprising administering to the mammal one or more fosinopril tablets comprising fosinopril in one or more of its free acid form and its pharmaceutically acceptable salts, colloidal silicon dioxide, and talc.

39. The method according to claim 38, wherein the tablet further comprises a second active ingredient.

40. The method according to claim 39, wherein the second active ingredient comprises a diuretic comprising one or more of chlorthalidone, furosemide, triameterene, amiloride, spironolactone, and thiazide diuretics.

41. The method according to claim 40, wherein the thiazide diuretic comprises one or more of chlorothiazide, hydrochlorothiazide, flumethiazide and bendroflumethiazide.

42. The method according to claim 41, wherein the thiazide diuretic comprises hydrochlorothiazide.

43. The method according to claim 38, wherein greater than approximately 98% of an initial amount of fosinopril remains after storage for three months at 40°C and 75% relative humidity as measured by high performance liquid chromatography.

44. The storage stable tablet of claim 38, wherein greater than approximately 99% of an initial amount of fosinopril sodium remains after storage for one week at 60°C as measured by high performance liquid chromatography.